Introduction: Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This study estimates the cost-effectiveness of KTE-X19 to treat adults with R/R ALL from a US payer perspective.
Methods: The model had two components: a decision-tree, where pre-infusion costs for patients who ultimately did not receive KTE-X19 are accounted for, followed by a partitioned survival analysis, where all KTE-X19 infused patients would enter the three-state (pre-progression, progressed disease, death) model. Comparators included current standard of care treatments, i.e., blinatumomab (BLIN), inotuzumab ozogamicin (INO), and salvage chemotherapy (CHEMO). Both standard parametric and mixture cure models were used to model survival. Efficacy, safety, healthcare resource utilization, and health state utility inputs were derived from the ZUMA-3 trial (NCT02614066) and literature. Cost inputs were derived from literature or publicly available sources. Outcomes and costs were discounted 3% annually. Results of KTE-X19 versus comparators are reported as total and incremental life-years (LYs), quality-adjusted life-years (QALYs), costs, and resulting incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses (PSA) and key scenario analyses were also performed.
Results: In the base case, incremental QALYs for KTE-X19 were 2.44, 3.26, and 4.61 versus BLIN, INO, and CHEMO, respectively. Incremental costs were $50,913, $251,532, and $432,027, respectively, resulting in ICERs of $20,843/QALY (versus BLIN), $77,271/QALY (versus INO), and $93,768/QALY (versus CHEMO). Deterministic sensitivity analysis results were most sensitive to subsequent allogeneic stem cell transplant rates and post-progression utilities. PSA found that KTE-X19 is 78.4%, 74.0%, and 75.4% likely to be cost-effective versus BLIN, INO, and CHEMO, respectively. Across most scenarios, at a willingness-to-pay (WTP) threshold of $150,000/QALY, KTE-X19 was cost-effective versus all treatments.
Conclusions: Compared to current options for adults with R/R ALL, KTE-X19 is cost-effective, driven primarily by improved survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309154 | PMC |
| http://dx.doi.org/10.1007/s12325-022-02201-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Am J Hematol
March 2024
Hematology Department, Nantes University Hospital, Nantes, France.
Article Synopsis
- The presence of donor Vγ9Vδ2 T-cells after haploidentical hematopoietic stem cell transplant (h-HSCT) is linked to better disease-free survival, as these cells can target tumor cells without triggering severe side effects.
- A clinical study assessed the safety of generating these T-cells by combining zoledronic acid (ZA) with interleukin-2 (IL-2), showing that the procedure is safe and successfully increases T-cell numbers in patients.
- The study's outcomes suggest potential for further research into using this immunotherapy to reduce relapse rates after h-HSCT, indicating that more extensive trials may come next.
Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case-control study within the French nationwide claims database.
Pharmacoepidemiol Drug Saf
December 2023
INSERM CIC-P 1401, Bordeaux PharmacoEpi, Université de Bordeaux, Bordeaux, France.
Article Synopsis
- The study aimed to compare cancer risks in multiple sclerosis patients who used exclusive immunosuppressants (IS) versus immunomodulators (IM) from 2008 to 2014, using data from the French claims database.
- Among 28,720 patients, 407 developed cancer, showing a significant 37% higher risk for those using IS compared to IM, particularly within the first 2 years of use.
- However, the study found no increased cancer risk associated with prolonged use of IS solely prescribed for MS, suggesting no causal link between these medications and cancer for that duration.
[Real-life survival of idiopathic pulmonary fibrosis with anti-fibrotic medication].
Rev Mal Respir
May 2023
Service de pneumologie et des explorations fonctionnelles respiratoires, CHRU de Tours, Tours, France; Inserm UMR 1100, université François-Rabelais, faculté de médecine de Tours, Tours, France.
Introduction: Idiopathic pulmonary fibrosis (IPF) is an irreversible fibrosing disease with median survival at diagnosis of 2-5 years. That said, pirfenidone and nintedanib slow down the gradual decline in respiratory function. Clinical trials have shown that while they are not curative, these drugs reduce mortality and increase survival time compared to placebo.
View Article and Find Full Text PDFPurpose: The aim of this study was to compare the diagnostic performance of the rabbit visual pattern versus the one endorsed by the EANM/SNMMI for the diagnosis of parkinsonian syndromes in PET/MRI.
Patients And Methods: The 18F-DOPA PET images of 129 consecutive patients (65 Park+ and 64 controls) with 1 year of clinical follow-up were reviewed independently by 5 experienced readers on the same imaging workstation, blinded to the final clinical diagnosis. Two visual methods were assessed independently, with several days to months of interval: the criteria endorsed by EANM/SNMMI and the "rabbit" shape of the striate assessed on 3D MIP images.
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.
Expert Rev Clin Pharmacol
September 2022
INSERM CIC-P 1401, Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France.
Objectives: To conduct the direct comparison of abiraterone acetate and docetaxel for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings.
Methods: Data were extracted from the French nationwide claims database (SNDS) on all men aged ≥40 years starting first-line treatment with abiraterone acetate or docetaxel for mCRPC in 2014. A high-dimensional propensity score including 100 baseline characteristics was used to match patients of both groups and form two comparative cohorts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!